Ebola: as ZMapp stocks run out doctors turn to alternative treatments | WHAT REALLY HAPPENED

Ebola: as ZMapp stocks run out doctors turn to alternative treatments

ZMapp is for now out of the picture. There are no more stocks anywhere in the world. The Food and Drug Administration (FDA) in the United States has promised the company more than $42m (£27.6m) to speed up production and trials, but the drug consists of three monoclonal antibodies that have to be grown in the leaves of genetically modified tobacco plants, which takes months. It is also very expensive, which means that mass production for Africa is unlikely.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA